Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ORIC 114

Next Previous
Drug Profile

ORIC 114

Alternative Names: ORIC-114; VRN 07

Latest Information Update: 06 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Voronoi
  • Developer ORIC Pharmaceuticals; Voronoi
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer
  • Preclinical HER2 positive breast cancer

Most Recent Events

  • 25 Feb 2025 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT06816992)
  • 10 Feb 2025 ORIC Pharmaceuticals plans a phase I trial in Non-small cell lung cancer (Late stage disease, Metastatic disease, combination therapy) in Australia, Canada and the US (PO) (NCT06816992)
  • 14 Jan 2025 ORIC Pharmaceuticals enters into a supply agreement with Janssen Research & Development, to evaluate ORIC-114, in combination amivantamab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top